PT2510011E - Anticorpos monoclonais que se ligam a b7h6 e suas utilizações - Google Patents

Anticorpos monoclonais que se ligam a b7h6 e suas utilizações Download PDF

Info

Publication number
PT2510011E
PT2510011E PT108131160T PT10813116T PT2510011E PT 2510011 E PT2510011 E PT 2510011E PT 108131160 T PT108131160 T PT 108131160T PT 10813116 T PT10813116 T PT 10813116T PT 2510011 E PT2510011 E PT 2510011E
Authority
PT
Portugal
Prior art keywords
bind
monoclonal antibodies
monoclonal
antibodies
Prior art date
Application number
PT108131160T
Other languages
English (en)
Portuguese (pt)
Inventor
Michel Pierres
Eric Vivier
Myriam Baratin
Original Assignee
Inst Nat Santé Et De La Rech Médicale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43827827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2510011(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inst Nat Santé Et De La Rech Médicale filed Critical Inst Nat Santé Et De La Rech Médicale
Publication of PT2510011E publication Critical patent/PT2510011E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT108131160T 2009-12-09 2010-12-08 Anticorpos monoclonais que se ligam a b7h6 e suas utilizações PT2510011E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28501809P 2009-12-09 2009-12-09

Publications (1)

Publication Number Publication Date
PT2510011E true PT2510011E (pt) 2014-12-12

Family

ID=43827827

Family Applications (1)

Application Number Title Priority Date Filing Date
PT108131160T PT2510011E (pt) 2009-12-09 2010-12-08 Anticorpos monoclonais que se ligam a b7h6 e suas utilizações

Country Status (18)

Country Link
US (2) US8822652B2 (enExample)
EP (1) EP2510011B2 (enExample)
JP (2) JP2013513380A (enExample)
CN (2) CN102741290B (enExample)
BR (1) BR112012013975B8 (enExample)
CA (1) CA2783740C (enExample)
DK (1) DK2510011T3 (enExample)
EA (1) EA024629B1 (enExample)
ES (1) ES2523472T3 (enExample)
HR (1) HRP20141170T1 (enExample)
IN (1) IN2012DN04908A (enExample)
MX (1) MX2012006443A (enExample)
PL (1) PL2510011T3 (enExample)
PT (1) PT2510011E (enExample)
RS (1) RS53667B1 (enExample)
SI (1) SI2510011T1 (enExample)
SM (1) SMT201400184B (enExample)
WO (1) WO2011070443A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US12492376B2 (en) 2009-10-29 2025-12-09 The Trustees Of Dartmouth College T-cell receptor-deficient T cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
MX2012006443A (es) 2009-12-09 2012-06-28 Inst Nat Sante Rech Med Anticuerpos monoclonales que se enlazan a b7h6 y usos de los mismos.
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
RU2014104695A (ru) 2011-09-13 2015-10-20 Дойчес Кребсфоршунгсцентрум Терапевтически активное моноклональное антитело в7-н6 против полипептида в7-н6
CN104395344B (zh) * 2012-05-07 2019-08-13 达特茅斯大学理事会 抗b7-h6抗体、融合蛋白及其使用方法
WO2014044799A1 (en) * 2012-09-21 2014-03-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for the diagnosing of inflammatory conditions involving detecting, identifying or assaying for soluble b7-h6 polypeptides
EP2711707A1 (en) 2012-09-21 2014-03-26 Institut Gustave Roussy Methods and kits for predicting the sensitivity of a subject to chemotherapy
CN114634569B (zh) * 2016-04-15 2024-08-20 达特茅斯大学理事会 高亲和力b7-h6抗体和抗体片段
WO2017214433A1 (en) * 2016-06-09 2017-12-14 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with flt3 inhibitors
JP7500005B2 (ja) * 2017-11-16 2024-06-17 ヴィスカ・バイオ・インコーポレイテッド リソソーム誘発性免疫原性細胞死のシステムおよび方法
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
JP7579795B2 (ja) 2019-02-21 2024-11-08 マレンゴ・セラピューティクス，インコーポレーテッド ＮＫｐ３０に結合する抗体分子およびその使用
WO2021138474A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
CA3164182A1 (en) * 2020-01-17 2021-07-22 Liu XUE Anti-nkp30 antibodies and methods of use
CN117321087A (zh) 2021-03-26 2023-12-29 先天制药公司 包含与细胞因子融合用于nk细胞衔接的nkp46结合位点、癌抗原结合位点的多特异性蛋白质
CN117616050A (zh) 2021-06-09 2024-02-27 先天制药公司 与nkp46、细胞因子受体、肿瘤抗原和cd16a结合的多特异性蛋白质
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
CN114395045B (zh) * 2021-12-07 2023-06-09 合肥天港免疫药物有限公司 B7h6抗体及其应用
CN114395043B (zh) * 2021-12-07 2023-07-11 合肥天港免疫药物有限公司 Ncr3lg1抗体及其应用
CN114395047B (zh) * 2021-12-07 2023-11-07 合肥天港免疫药物有限公司 双特异性抗体及其应用
CN114395044B (zh) * 2021-12-07 2023-12-29 合肥天港免疫药物有限公司 重组抗体及其应用
CN114634574B (zh) * 2022-04-18 2022-12-20 先进生物(苏州)有限公司 抗B7H6的scFv抗体、其编码基因及其应用
WO2024005422A1 (ko) * 2022-06-29 2024-01-04 고려대학교 산학협력단 Nkp30 결합력이 향상된 b7-h6 변이체
CN120265755A (zh) * 2022-11-16 2025-07-04 德国癌症研究公共权益基金会 用于疾病治疗的t细胞-nk细胞相互作用抑制剂
WO2024208818A1 (en) 2023-04-04 2024-10-10 Innate Pharma Modular chimeric antigen receptor
CN121628833B (zh) * 2026-02-03 2026-05-08 浙江省中医院、浙江中医药大学附属第一医院（浙江省东方医院） 人源壶腹癌细胞系dpc-x5及其应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4486414A (en) 1983-03-21 1984-12-04 Arizona Board Of Reagents Dolastatins A and B cell growth inhibitory substances
US4883662A (en) 1984-04-10 1989-11-28 Clinical Biotechnologies, Inc. Method of increasing natural killer cell population of cancer patients
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4816444A (en) 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
IL89220A (en) 1988-02-11 1994-02-27 Bristol Myers Squibb Co Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them
WO1989012624A2 (en) 1988-06-14 1989-12-28 Cetus Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5082833A (en) 1988-06-30 1992-01-21 Shamsuddin Abulkalam M Reduction of cell proliferation and enhancement of nk-cell activity
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5076973A (en) 1988-10-24 1991-12-31 Arizona Board Of Regents Synthesis of dolastatin 3
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US4978744A (en) 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
US5138036A (en) 1989-11-13 1992-08-11 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
JP3202999B2 (ja) 1991-01-31 2001-08-27 協和醗酵工業株式会社 肝移行性リポソーム製剤
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US5410024A (en) 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5556623A (en) 1993-03-30 1996-09-17 Eli Lilly And Company Antibody-drug conjugates
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5504191A (en) 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5521284A (en) 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5530097A (en) 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5554725A (en) 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
EP0871490B1 (en) 1995-12-22 2003-03-19 Bristol-Myers Squibb Company Branched hydrazone linkers
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
CA2282504A1 (en) 1997-02-25 1998-08-27 Jun-Ping Xu Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
AU2769101A (en) * 2000-01-07 2001-07-24 Millennium Pharmaceuticals, Inc. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
US20040152105A1 (en) * 2002-09-06 2004-08-05 Cytos Biotechnology Ag. Immune modulatory compounds and methods
JP2008540569A (ja) * 2005-05-12 2008-11-20 ザイモジェネティクス， インコーポレイテッド 免疫系を調整するためにＢ７ファミリーメンバーであるｐＮＫｐ３０を使用する方法
CA2682605A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
US7858759B2 (en) * 2007-10-04 2010-12-28 Zymogenetics, Inc. Anti-zB7H6 antibody-drug conjugates
MX2012006443A (es) 2009-12-09 2012-06-28 Inst Nat Sante Rech Med Anticuerpos monoclonales que se enlazan a b7h6 y usos de los mismos.

Also Published As

Publication number Publication date
CN104926942B (zh) 2018-09-14
CN104926942A (zh) 2015-09-23
RS53667B1 (sr) 2015-04-30
WO2011070443A1 (en) 2011-06-16
JP6212181B2 (ja) 2017-10-11
EA201270654A1 (ru) 2013-02-28
US8822652B2 (en) 2014-09-02
IN2012DN04908A (enExample) 2015-09-25
ES2523472T3 (es) 2014-11-26
HRP20141170T1 (hr) 2015-01-30
CN102741290A (zh) 2012-10-17
SMT201400184B (it) 2015-01-15
BR112012013975A2 (pt) 2017-01-10
DK2510011T3 (en) 2014-12-01
JP2017031147A (ja) 2017-02-09
US20150056214A1 (en) 2015-02-26
US20130004432A1 (en) 2013-01-03
EP2510011B2 (en) 2021-03-31
CN102741290B (zh) 2015-04-22
SI2510011T1 (sl) 2014-12-31
CA2783740C (en) 2020-03-10
JP2013513380A (ja) 2013-04-22
BR112012013975B8 (pt) 2021-05-25
US9663577B2 (en) 2017-05-30
CA2783740A1 (en) 2011-06-16
PL2510011T3 (pl) 2015-02-27
EP2510011A1 (en) 2012-10-17
EA024629B1 (ru) 2016-10-31
EP2510011B1 (en) 2014-09-17
BR112012013975B1 (pt) 2021-01-12
MX2012006443A (es) 2012-06-28

Similar Documents

Publication Publication Date Title
SI2510011T1 (sl) Monoklonska protitelesa, ki veĹľejo B7H6 in njihova uporaba
IL215649A (en) Monoclonal antibodies against TNF-α and their use
SG10201601279SA (en) Monoclonal Antibody STRO-4
EP2331579A4 (en) MONOCLONAL ANTIBODIES
EP2374883A4 (en) ANTI-CD4 ANTIBODIES
EP2494062A4 (en) ANTI-GLP-1R ANTIBODIES AND THEIR USES
AP2011005859A0 (en) Humanized antibodies that bind to CD19 and their uses.
IL218724A0 (en) Endoglin antibodies
IL209309A0 (en) Anti-fn14 antibodies and uses thereof
ZA201202227B (en) Monoclonal antibodies
SI3702371T1 (sl) Protitelesa proti FGFR3 in postopki za uporabo le-teh
ZA201207484B (en) Humanized anti-egfl7 antibodies and methods using same
IL216731A (en) And antibodies against p95 – her2 and their uses
ZA201105573B (en) Novel anti-alpha5beta1 antibodies and uses thereof
IL216304A0 (en) Blocking anti- dkk-1 antibodies and their uses
IL200168A0 (en) Monoclonal anti-cxcl13 antibodies
IL220536A0 (en) Anti - bv8 antibodies and uses thereof
GB0903151D0 (en) Antibody uses and methods
IL214755A (en) A monoclonal antibody against rhd and various aspects associated with it
IL214527A0 (en) Anti-mst1r antibodies and uses thereof
IL206898A0 (en) HUMANIZED ANTI-HUMAN a9-INTEGRIN ANTIBODY AND USES THEREOF
GB0906115D0 (en) Antibody and uses thereof
EP2540742A4 (en) MONOCLONAL ANTIBODIES OF ANTI-CYR61 PROTEIN AND USES THEREOF